Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

MLA

Nijhuis, Monique, et al. “Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.” The Journal of Infectious Diseases, vol. 200, no. 5, Sept. 2009, pp. 698–709. EBSCOhost, https://doi.org/10.1086/605329.

APA

Nijhuis, M., Wensing, A. M. J., Bierman, W. F. W., de Jong, D., Kagan, R., Fun, A., Jaspers, C. A. J. J., Schurink, K. A. M., van Agtmael, M. A., & Boucher, C. A. B. (2009). Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. The Journal of Infectious Diseases, 200(5), 698–709. https://doi.org/10.1086/605329

Chicago

Nijhuis, Monique, Annemarie M J Wensing, Wouter F W Bierman, Dorien de Jong, Ron Kagan, Axel Fun, Christian A J J Jaspers, Karin A M Schurink, Michael A van Agtmael, and Charles A B Boucher. 2009. “Failure of Treatment with First-Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V.” The Journal of Infectious Diseases 200 (5): 698–709. doi:10.1086/605329.